Abolis' MINE Platform Accelerates Fermentation Ingredient R&D, Cutting Time-to-Market
French biotech Abolis has launched MINE, a microbial intelligence platform designed to streamline fermentation-derived ingredient development. The system promises to reduce R&D cycles and facilitate faster commercialisation of biotics and novel compounds.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Paris, France — 01 October 2026
French biotech firm Abolis Biotechnologies has unveiled its Microbial INtelligence Explorer (MINE) platform, aiming to significantly accelerate the development and commercialisation of fermentation-derived ingredients and biotics. The platform integrates genomic and multi-omics data with existing experimental and industrial insights, providing a structured framework for R&D teams to make precise decisions on product innovation and process scalability. This data-driven approach is positioned to minimise the extensive trial-and-error often associated with microbial research, allowing supplement manufacturers to bring novel ingredients to market more efficiently.
MINE addresses the critical industry challenge of translating vast microbial datasets into actionable product development strategies. According to Sylvia Julien, General Manager of the MINE business unit at Abolis, the platform helps R&D teams identify promising microorganisms and optimal process parameters early in the development cycle, reducing the investment in premature lab testing and scale-up efforts. The technology, initially developed through the French government-backed Metapath industrial programme's Microbiome Studio, has been refined via collaborations with industrial partners, validating its commercial applicability.
The launch of MINE extends Abolis' existing expertise in strain engineering, enzyme modelling, bioprocess development, and scale-up support. Cyrille Pauthenier, co-founder and CEO of Abolis, states the platform provides a clearer route from microbial potential to industrially relevant programmes, strengthening decision support across the entire product lifecycle. This capability is crucial for ingredient manufacturers seeking to improve fermentation performance and explore alternative production routes for existing molecules, aligning with broader industry trends towards optimising microbial production systems, as exemplified by recent developments from Sensient and Tetra Pak in fermentation technologies.
What this means for United Kingdom
UK supplement manufacturers reliant on fermentation-derived ingredients or developing new biotics will see direct benefits. The MINE platform offers a competitive advantage by enabling faster innovation cycles and reducing the financial risk associated with R&D, potentially cutting development costs by 10-20% for complex microbial strains. Procurement leads should assess supplier adoption of such platforms, as it impacts lead times and ingredient stability. Regulatory compliance for novel food status (under FSA and EFSA guidance) could be expedited with robust, data-backed development dossiers generated via MINE, particularly for novel probiotics or postbiotics, streamlining market access within 18-24 months.
The increasing focus on precision fermentation also means contract manufacturers like Supplement Factory must evaluate integrating advanced bioprocess optimisation tools to maintain a competitive edge and support brand owners seeking efficiency gains.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.